2023
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases
Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases. JAMA Oncology 2023, 9: 197-205. PMID: 36454580, PMCID: PMC9716438, DOI: 10.1001/jamaoncol.2022.5610.Peer-Reviewed Original ResearchConceptsErbB2-positive metastatic breast cancerMetastatic breast cancerPlacebo-combination groupPositive metastatic breast cancerNew brain lesionsBrain metastasesOverall survivalSubgroup analysisBrain lesionsBreast cancerIntracranial progression-free survivalPlacebo-controlled clinical trialIntracranial objective response rateStable brain metastasesMedian overall survivalObjective response rateProgression-free survivalExploratory subgroup analysisGreater clinical benefitCNS-PFSHER2CLIMB trialIntracranial outcomesFirst progressionMedian ageClinical benefit
2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
Mamounas EP, Untch M, Mano MS, Huang C, Geyer CE, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin AK, Alcedo JC, Kuehn T, Wapnir I, Fontana A, Hackmann J, Polikoff J, Saghatchian M, Brufsky A, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Annals Of Oncology 2021, 32: 1005-1014. PMID: 33932503, DOI: 10.1016/j.annonc.2021.04.011.Peer-Reviewed Original ResearchConceptsInvasive disease-free survivalAdjuvant T-DM1Residual invasive diseaseT-DM1 armNeoadjuvant chemotherapyEarly breast cancerHigh-risk tumorsRisk of recurrenceT-DM1Central nervous systemPeripheral neuropathyCNS recurrenceInvasive diseaseBreast cancerHER2-positive eBC patientsInvasive early breast cancerAnthracycline-based neoadjuvant chemotherapyHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2Overall riskAdjuvant trastuzumab emtansineBaseline peripheral neuropathyLonger PN durationMore grade 3
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. Patients
2001
Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors
Claus E, Chu P, Howe C, Davison T, Stern D, Carter D, DiGiovanna M. Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors. Experimental And Molecular Pathology 2001, 70: 303-316. PMID: 11418009, DOI: 10.1006/exmp.2001.2366.Peer-Reviewed Original ResearchConceptsHigh nuclear gradeEstrogen receptorNuclear gradePeriductal fibrosisProgesterone receptorNeu overexpressionComedo histologyPR expressionExpression of ERHER-2/neuAssociated invasive carcinomaCases of DCISHospital-based surveyBiology of DCISPotential clinical implicationsDuctal carcinomaTumor sizePathologic markersInvasive carcinomaNeu expressionBreast carcinomaCase subjectsDCISClinical implicationsMorphologic featuresAdenoid cystic carcinoma: A retrospective clinical review
Khan A, DiGiovanna M, Ross D, Sasaki C, Carter D, Son Y, Haffty B. Adenoid cystic carcinoma: A retrospective clinical review. International Journal Of Cancer 2001, 96: 149-158. PMID: 11410883, DOI: 10.1002/ijc.1013.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalPerineural invasionNeu positivityCystic carcinomaSurvival rateOral cavity/oropharynxRecurrence-free survival ratesDistant recurrence-free survivalDistant recurrence ratesMinor gland tumorsCause-specific survivalOverall survival rateAmerican Joint CommitteeRetrospective clinical reviewSquamous cell carcinomaHigh tumor gradeTerms of survivalDecreased OSCancer criteriaBrain metastasesNerve invasionPalliative casesChart reviewMargin statusOverall survivalCommentary: Extracting functional information from tissues
DiGiovanna M. Commentary: Extracting functional information from tissues. Molecular Diagnosis 2001, 6: 13-15. DOI: 10.1054/modi.2001.21896.Peer-Reviewed Original ResearchExtracting Functional Information From Tissues
DiGiovanna M. Extracting Functional Information From Tissues. Molecular Diagnosis 2001, 6: 13-15. PMID: 11257207, DOI: 10.1007/bf03262099.Peer-Reviewed Original Research
1997
Phosphorylation Sensitivity of the Commonly Used Anti-p185neu/erbB2Monoclonal Antibody Clone 3B5 Suggests Selective Usage of Autophosphorylation Sites
DiGiovanna M. Phosphorylation Sensitivity of the Commonly Used Anti-p185neu/erbB2Monoclonal Antibody Clone 3B5 Suggests Selective Usage of Autophosphorylation Sites. Analytical Biochemistry 1997, 247: 167-170. PMID: 9126388, DOI: 10.1006/abio.1997.9919.Peer-Reviewed Original Research
1996
Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
DiGiovanna M, Carter D, Flynn S, Stern D. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. British Journal Of Cancer 1996, 74: 802-806. PMID: 8795585, PMCID: PMC2074709, DOI: 10.1038/bjc.1996.439.Peer-Reviewed Original ResearchConceptsHER-2/neuPrognostic indicatorBreast carcinomaInvasive breast carcinomaHER-2/ neuHuman breast tumorsFunctional assaysHuman breast carcinomaClinicopathological characteristicsPoor prognosisInvasive human breast tumoursLarge seriesBreast tumorsNeuMonoclonal antibodiesCarcinomaTumorsAntibodiesDifferent reportsOverexpressionReportAssaysPrognosis